[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100583791":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":32,"locations":26,"responsibleParty":38,"collaborators":26,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":26,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":26,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":26,"overallStatus":60,"whyStopped":26,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":26},{"fullName":5,"class":6},"Qilu Hospital of Shandong University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Olive oil","PLACEBO_COMPARATOR","Oral administration of olive oil : 2 grams per dose, once daily, for a duration of 24 weeks.",[13],"Dietary Supplement: Olive Oil",{"label":15,"type":16,"description":17,"interventionNames":18},"Antarctic krill oil","EXPERIMENTAL","Oral administration of antarctic krill oil : 2 grams per dose, once daily, for a duration of 24 weeks.",[19],"Drug: Krill oil",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Krill oil","Antarctic krill oil was used for intervention in the experimental group.",[15],null,{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":26},"DIETARY_SUPPLEMENT","Olive Oil","Olive oil was used for intervention in the placebo group.",[9],[33],{"name":34,"role":35,"phone":36,"phoneExt":26,"email":37},"Yuankai Zhang Qilu Hospital of Shandong University","CONTACT","+86 18560082587","drzhangyk@163.com",{"type":39,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100583791","phase-2-antarctic-krill-oil-for-knee-osteoarthritis-pain-100583791",false,"NCT06880926","Antarctic Krill Oil for Knee Osteoarthritis Pain","A Randomized, Double-Blind, Parallel-Controlled, Multicenter Clinical Trial of Antarctic Krill Oil in the Management of Knee Osteoarthritis Pain","Inclusion Criteria:\n\n* Aged 45-75 years；\n* Clinically diagnosed with knee osteoarthritis per the Chinese Guidelines for the Diagnosis and Treatment of Osteoarthritis (2018 edition) issued by the Chinese Medical Association, with Kellgren-Lawrence grade 1-3；\n* Knee pain Visual Analog Scale (VAS) score between 4.0 and 8.0；\n* Ability to comprehend and complete VAS and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) assessments；\n* Willingness and ability to undergo knee MRI examinations.\n\nExclusion Criteria:\n\n* Ipsilateral hip osteoarthritis;\n* Diagnosis of rheumatoid arthritis (RA), ankylosing spondylitis, sarcoidosis, amyloidosis, or any other inflammatory arthritis (e.g., gout, pseudogout);\n* Chronic pain syndromes, fibromyalgia, or comorbidities that may confound knee pain assessment;\n* Pain intensity in the lower extremities or back equal to or greater than knee pain;\n* Arthroscopic or open knee surgery within the preceding 12 months or planned during the study period;\n* Oral, intra-articular, or intramuscular corticosteroid use within 6 months prior to screening or during the study;\n* Intra-articular hyaluronic acid injection within 6 months prior to screening or during the study;\n* High-dose NSAID use (≥ maximum recommended daily dose for osteoarthritis pain relief) within 1 month prior to screening, including but not limited to: Diclofenac ≥150 mg\u002Fday; Aceclofenac ≥100 mg\u002Fday; Meloxicam ≥15 mg\u002Fday; Naproxen ≥1,000 mg\u002Fday; Piroxicam ≥20 mg\u002Fday; Ibuprofen \\>2,400 mg\u002Fday (Exempt if a ≥4-week washout period is completed prior to Day 1);\n* Bleeding disorders or anticoagulant use within 1 month (except low-dose aspirin ≤150 mg\u002Fday);\n* Regular use of glucosamine, fish oil, or other supplements unless a ≥4-week washout period (≥3 months for fish oil) is completed prior to Day 1;\n* Hypersensitivity to trial medications or seafood;\n* Administration of any medication within 6 months prior to Day 1 that may interfere with study outcomes, as judged by investigators;\n* Pregnancy (positive urine test at screening or Day 1), lactation, or inadequate contraception;\n* History of alcoholism, substance abuse, major systemic diseases (e.g., renal, cardiac, hepatic, or gastrointestinal disorders), or conditions deemed by investigators to compromise study participation or data integrity;\n* Uncontrolled hypertension (screening blood pressure ≥140\u002F90 mmHg) unless confirmed as non-hypertensive or well-controlled by a specialist;\n* Inability to provide informed consent.","ALL","45 Years","75 Years",{"count":51,"type":52},116,"ESTIMATED","INTERVENTIONAL",[55],"PHASE2","The goal of this clinical trial is to evaluate the effectiveness and safety of Antarctic Krill Oil (AKO) as a dietary supplement in managing pain associated with knee osteoarthritis (OA). The main questions it aims to answer are:\n\n①Does AKO reduce daily pain intensity in participants with moderate knee OA?\n\n②What adverse effects do participants experience when taking AKO?\n\nResearchers will conduct a randomized, double-blind study comparing AKO to a placebo (identical appearance without active components) to assess:\n\n* Changes in joint pain severity; ②Functional improvement in daily activities; ③Biochemical safety parameters,etc.",[58,59],"Osteoarthritis (OA) of the Knee","Osteoarthritis Knee Pain","NOT_YET_RECRUITING","2025-03-16",{"date":63,"type":64},"2025-03-18","ACTUAL",{"date":66,"type":52},"2025-04-01",{"date":68,"type":52},"2026-02-28",{"name":5,"class":6}]